Anti-Müllerian hormone and ovarian morphology in women with hypothalamic hypogonadism by Alemyar, A. (Amoon) et al.
C L I N I C A L  R E S E A R C H  A R T I C L E
e2008  J Clin Endocrinol Metab, May 2020, 105(5):e2008–e2014  https://academic.oup.com/jcem doi:10.1210/clinem/dgaa116
Anti-Müllerian Hormone and Ovarian Morphology in 
Women With Hypothalamic Hypogonadism
Amoon Alemyar, Anne-Lotte L.F. van der Kooi, and Joop S.E. Laven
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus 
University Medical Centre, 3015 GD Rotterdam, The Netherlands
ORCiD numbers: 0000-0003-3056-1581 (A. Alemyar); 0000-0003-0497-3814 (A.-L. L.F. van der Kooi); 
0000-0002-5444-9845 (J. S.E. Laven).
Context: Different phenotypical features of women with hypothalamic hypogonadism (HH), 
also known as World Health Organization-1 anovulation, including ovarian morphology, have 
been scarcely described in large cohorts. Some studies have reported increased levels of anti-
Müllerian hormone (AMH) in women with HH.
Objective: To assess whether women with HH, compared with healthy controls, have increased 
serum levels of AMH and what proportion of these women erroneously meet the Rotterdam 
Criteria for Polycystic Ovarian Syndrome (PCOS).
Design, Setting and Participants: Retrospective cohort study in a Dutch academic medical center 
including 83 women with neither anovulation nor menstrual cycle disorders (healthy controls), 
159 women with HH and 3640 women with PCOS. Age matching was used between the HH and 
PCOS group (1:2 ratio) to create a second group consisting of 318 age-matched women with 
PCOS.
Intervention: None.
Main outcome measures: AMH levels and ovarian morphology.
Results: Median AMH serum levels for the HH group were 3.8 (<0.1–19.8), compared with 7.5 
(<0.1–81.0) in the PCOS group and 1.9 (<0.1–21.5) in the control group (P < 0.001). In the HH 
group, 58 (36%) erroneously met the Rotterdam Criteria for PCOS (meeting 2 of 3 criteria).
Conclusions: AMH levels are increased in women with HH. We hypothesize that this increase, 
although there was no increase in follicle count, may be explained by the presence of a relatively 
large pool of antral follicles smaller than 2 mm in diameter, that are undetectable by transvaginal 
ultrasound. This study highlights the importance of measuring gonadotropins and estradiol 
before diagnosing a patient with PCOS. (J Clin Endocrinol Metab 105: e2008–e2015, 2020)
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Anovulation is the state in which a woman does not ovulate, often resulting in oligomenorrhea 
or amenorrhea (1). The World Health Organization 
(WHO) identifies 3 distinct groups: WHO-1 is char-
acterized by dysfunction of the hypothalamic-pituitary 
axis to produce gonadotropins (LH and FSH) resulting 
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in anovulation and in low estrogens. This category of 
anovulation is also known as hypothalamic hypo-
gonadism (HH) (2, 3). HH may be caused by excessive 
exercise or physical stress, or from eating disorders such 
as anorexia nervosa or bulimia (4). In about 5% to 10% 
of all anovulatory women, HH seems to be the cause 
(3). Patients with HH are at risk of osteoporosis (5, 6) 
and cardiovascular disease (7, 8), as a result of their per-
sistent low estrogen levels (7).
By far the largest part of women with anovulation are 
classified in the WHO-2 category, which is characterized 
by normal FSH and estradiol (E2) levels. Most women 
in this category can be classified as having polycystic 
ovary syndrome (PCOS). In these women, irregular 
cycles are accompanied by hyperandrogenism and poly-
cystic ovarian morphology (PCOM) (9–11).
Anti-Müllerian hormone (AMH) is produced in the 
ovary by granulosa cells of small growing pre-antral 
and antral follicles. AMH inhibits the recruitment of 
primordial follicles out of the primordial follicle pool, 
decreases FSH sensitivity of individual follicles, and in-
hibits aromatase activity (consequently increasing an-
drogen levels in the ovary) (12, 13). Because the ovarian 
follicle pool gradually diminishes over the course of a 
women’s reproductive lifetime, a simultaneous decrease 
in AMH levels occurs (14, 15).
In the past, higher follicle number per ovary (FNPO) 
in women with HH compared with controls has been 
reported (16). This may lead to the suspicion that, when 
follicle count reaches the number required for the char-
acterization of PCOM, women with HH may be mis-
diagnosed with PCOS, if gonadotropin levels FSH and 
estrogen serum levels are not taken into account (17).
The primary goal of this paper is to assess whether 
women with HH have increased AMH serum levels 
compared with women with regular cycles and com-
pared with women with PCOS. The secondary goal 
of this paper is to assess whether PCOM occurs more 
often in women with HH than in women with regular 
cycles and in women with PCOS. Finally, we wanted to 
evaluate how often the negligence of measuring serum 
levels of FSH, LH, and E2 would falsely lead to a PCOS 
diagnosis instead of the correct HH diagnosis.
Materials and Methods
Study design
In this retrospective single-center study, patients with cycle 
disorders and anovulation who visited the reproductive endo-
crinology and infertility clinic of the Erasmus University Medical 
Center in Rotterdam, The Netherlands, were consecutively 
selected between 1993 and 2018. Participants were not on fer-
tility medication during this visit; in case of oral contraceptive 
usage, they were seen at day 7 in their pill-free week. During 
their visit, extensive patient history, general health, family his-
tory, previous and current use of medication, and self-reported 
ethnicity was recorded. During physical examination, anthropo-
metric measurements (e.g., weight, height, body-mass index 
[BMI]) were assessed. Transvaginal ultrasonography was per-
formed to assess the number of antral follicles sized 2 to 10 mm 
in diameter, as well as to assess the ovarian volume in the left 
and right ovary. Laboratory blood tests were drawn randomly 
in the anovulatory cycles (fasting blood samples were taken 
with venipuncture) to collect data on endocrine and metabolic 
profiles. Blood samples were processed within 2 hours. Serum 
was produced and isolated by centrifuging blood samples at 
3000 rpm for a duration of 10 minutes at 20°C.
Patient selection
HH was defined as having low levels of gonadotropins 
(FSH and LH <2.0 U/L), low levels of E2 (<100 µmol/L), and 
either oligomenorrhea (menstrual periods being between 
35 days and 6 months apart) or amenorrhea (no menstruation 
for at least 6 months).
PCOS was defined as having normal levels of FSH, LH, 
and estrogen in addition to meeting 2 of the 3 criteria in 
the Rotterdam Criteria (1) oligomenorrhea/amenorrhea, (2) 
PCOM (defined as ≥ 12 follicles measuring 2 to 9 mm in diam-
eter in at least 1 ovary), and/or (3) signs of hyperandrogenism 
(17). In accordance to the Rotterdam Criteria for PCOS, 
hyperandrogenism was assessed and classified as either bio-
chemical or clinical hyperandrogenism (hirsutism). Biochemical 
hyperandrogenism was defined by the free androgen index 
(FAI) on the calculation of (testosterone/SHBG) × 100 (18). 
Biochemical hyperandrogenism was defined as having a FAI 
higher than 2.9. Clinical hyperandrogenism was assessed visu-
ally using the modified Ferriman-Gallwey score (19, 20), a 
standardized visual scale. Clinical hyperandrogenism was de-
fined as a modified Ferriman-Gallwey score of 5 or higher (18).
Healthy control women were selected from ongoing co-
hort studies at our department where, in addition to having a 
regular cycle pattern and no oligomenorrhea or amenorrhea, 
having normal levels of LH, FSH and estrogen as well as tes-
tosterone were required (21). Laboratory blood tests for the 
control group were drawn at days 3 through 5 of their natural 
cycle or seventh day of their pill-free week. This study was ap-
proved by the Medical Ethics Review Committee (institutional 
review board protocol number 2016-216, EMC) and written 
informed consent was obtained from all participants.
Hormone assays
Patient samples were stored at -20°C before hormone 
levels were determined. AMH levels were determined using 
double-antibody ELISA (Beckman Coulter, Inc., AMH Gen 
II assay, Webster, TX) (3). In patients who had their AMH 
levels measured before 2011, determination of AMH levels 
was done with an ultrasensitive ELISA (Immunotech-Coulter, 
Marseilles, France) (15, 22). These measurements were batch 
by batch-adjusted for comparability to AMH levels measured 
with the newer ELISA technology.
FSH, LH, and SHBG were determined using the Immulite 
platform assay. E2 was determined using radioimmunoassay 
(DPC). Androstenedione was determined using the Immulite 
2000 assay and the liquid chromatography tandem mass 
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/5/e2008/5805240 by Erasm
us U
niversiteit R
otterdam
 user on 28 M
ay 2020
e2010  Alemyar et al  AMH and Ovarian Morphology in Women J Clin Endocrinol Metab, May 2020, 105(5):e2008–e2014
spectometry assay. Testosterone was determined using liquid 
chromatography tandem mass spectometry.
Intra-assay and inter-assay coefficient variations for the 
Beckman Coulter Inc. Gen II assay AMH assay were <5% 
and <10% (3), for the Immunotech-Coulter AMH assay, these 
were <5% and 8%, respectively (15, 22). Intra-assay and 
inter-assay coefficient variations for FSH were <3.0% and 
<6.2%, for LH < 3.5% and <6.4%, for E2 <11% and <11%, 
for testosterone <3% and <5%, for androstenedione <8% and 
<11%, and for SHBG, respectively, <4% and <5% (23).
Statistical analysis
IBM SPSS Statistics 25 was used for statistical analysis. 
Continuous variables were presented as mean and standard 
deviation. Independent t-tests were used when comparing con-
tinuous variables that were normally distributed. Continuous 
variables that were not normally distributed were assessed 
using the Mann-Whitney U test, where these variables were 
presented as median and range. Normality was assessed using 
the Kolmogorov-Smirnov test. Categorical variables were 
presented as numbers and percentages. Differences between 
categorical variables such as elevated hormone levels were as-
sessed using a χ 2 test. If a cell contained less than 5 individuals, 
Fischer’s exact test was used for assessing the difference in cat-
egorical variables. Rstudio version 1.1.463 in combination 
with the packages “Matchit” (https://cran.r-project.org/web/
packages/MatchIt/index.html) and “foreign” (https://cran.r-
project.org/web/packages/foreign/index.html) were used to 
age match every HH patient with 2 PCOS patients (1:2 ratio). 
P values <0.05 were considered statistically significant.
Results
Study population
We identified 159 women with HH and 3640 women 
with PCOS. The control group consisted of 83 women 
with no cycle disorders or anovulation. We age-matched 
318 PCOS patients to the 159 patients in the HH 
group; this group will be referred to as the age-matched 
PCOS group.
The HH group did not statistically differ in age 
from the control group (26.67 ± 6.67 vs 28.37 ± 5.86). 
The PCOS group (N = 3640) was significantly 
older (27.62 ± 5.43) compared with the HH group 
(P < 0.05), but did not statistically differ in age from the 
control group.
The HH group’s BMI (23.06 ± 5.78) did not statistic-
ally differ from that of the control group (23.55 ± 3.74). 
The PCOS group had a higher BMI (26.95 ± 6.50) 
compared with both the HH (P < 0.001) and control 
group (P < 0.01). The increased BMI levels in the PCOS 
group persisted after age matching with the HH group 
(N = 318, BMI 27.07 ± 6.46) (Table 1).
AMH levels and ovarian morphology
Median AMH serum levels were significantly higher 
in the HH group compared with the control group (me-
dians 3.8 vs 1.9 µg/L, P < 0.001), but lower than AMH 
levels in the PCOS group (median AMH 7.5  µg/L) 
(Fig. 1A and Table 2). After age-matching, the difference 
in AMH levels between the PCOS group and HH group 
decreased. In the age-matched PCOS group, median 
AMH levels were 6.7 µg/L. These AMH levels remained 
significantly higher compared with both the HH group 
and the control group (P < 0.001) (Table 2).
Antral follicle count was not statistically different in 
the HH group compared with the control group (20.5 
[range 4.0–109.0] vs 21.5 [range 4.0–70.0]) (Table  2 
Table 1. Patient’s characteristics
Controls HH Age-Matched PCOS PCOS
N 83 159 318 3640
Age (years) 28.37 ± 5.86 26.67 ± 6.67 26.66 ± 6.63a 27.62 ± 5.43b
BMI (kg/m2) 23.55 ± 3.74 23.06 ± 5.78 27.07 ± 6.46c,d 26.95 ± 6.50c,d
Height (cm) 170.67 ± 7.32 168.32 ± 8.06 167.02 ± 7.62c 167.13 ± 7.56c
Weight (kg) 69.00 ± 14.27 65.38 ± 17.73 75.55 ± 19.06a,d 75.25 ± 18.76a,e
Insulin (pmol/L) 54.25 ± 27.32 60.67 ± 67.52 84.14 ± 76.65e,f 84.54 ± 147.39b
FSH (IU/L) 6.33 ± 2.49 3.09 ± 2.23e 5.25 ± 2.23d,f 5.56 ± 2.52c,e
LH (IU/L 3.78 ± 1.60 0.84 ± 0.90e 8.86 ± 7.07d,f 9.58 ± 8.96d,f
E2 (pmol/L) 169.60 ± 108.86 72.31 ± 119.09
e 270.08 ± 198.79d,f 278.59 ± 225.07d,f
Testosterone (nmol/L) 1.15 ± 0.51 0.78 ± 0.42e 1.91 ± 0.93d,f 1.95 ± 1.04d,f
Androstenedione 3.48 ± 1.20 3.05 ± 1.46 6.16 ± 2.59d,f 6.14 ± 2.70d,f
SHBG (nmol/L) 71.43 ± 44.13 62.88 ± 48.75 45.37 ± 29.77d,f 46.67 ± 29.85d,f
Free androgen index 1.47 ± 0.78 1.67 ± 1.79 5.50 ± 4.38d,f 5.65 ± 5.30d,f
Ferriman-Gallwey score 3.45 ± 1.97 4.64 ± 3.85 6.92 ± 5.14a,e 7.29 ± 5.55a,e
Values represent the mean ± standard deviation. 
BMI, body mass index, E2, estradiol; PCOS, polycystic ovarian syndrome.
 aP < 0.05 compared with controls. 
bP < 0.05 compared with HH. 
cP < 0.01 compared with controls 
dP < 0.001 compared with HH P values obtained through independent-samples t-test.
eP < 0.01 compared with HH. 
fP < 0.001 compared with controls. 
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and Fig. 1B). When looking at the follicle counts in each 
ovary separately, no differences were found in follicle 
counts. Similarly, no statistical difference was found 
for ovarian volume. However, the PCOS group showed 
increased antral follicle count (36.0, range 4.0–220.0) 
and total ovarian volume (17.52, range 1.26–200.62) 
compared with both the HH group and control group 
(P < 0.001). In the age-matched PCOS group, signifi-
cantly higher antral follicle count and total ovarian 
volume were also found compared with both the HH 
and control group, but were not higher than found in 
the PCOS group.
Table 3 shows that PCOM did not occur more often 
in the HH group compared with the control group 
(31.4% vs 24.1%). In the PCOS group, PCOM (87.5%) 
occurred more often compared with both the HH group 
and control group (P < 0.001). After age-matching, the 
difference between these groups remained large; PCOM 
occurred in 81.4% of the patients in the age-matched 
PCOS group.
Hyperandrogenism
Testosterone levels in the PCOS group and age-
matched PCOS group (1.95 ± 1.04  nmol/L and 
1.91 ± 0.93  nmol/L, respectively) were higher com-
pared with both the HH group and control group 
(0.78 ± 0.42 and 1.15 ± 0.51  nmol/L, respectively, 
P < 0.001).
SHBG and androstenedione levels did not statistic-
ally differ in the HH group compared with the control 
group. In the PCOS and age-matched PCOS group, 
SHBG was significantly lower, whereas androstenedione 
levels were significantly higher compared with both the 
HH group and the control group (Table 1).
Biochemical hyperandrogenism did not occur 
more often in the HH group compared with the 
Table 2. Patient’s characteristics
N
Controls HH Age-Matched PCOS PCOS
83 159 318 3640
AMH (µg/L)a 1.9 (<0.1–21.5) 3.8 (<0.1–19.8)b 6.7 (<0.1–39.8)b,c 7.5 (<0.1–81.0)b,c
Follicle count right ovary 10.0 (2.0–32.0) 9.0 (2.0–57.0) 17.0 (2.0–67.0)b,c 18.0 (2.0–110.0)b,c
Follicle count left ovary 9.5 (2.0–43.0) 9.0 (2.0–52.0) 16.0 (2.0–65.0)b,c 17.00 (2.0–115.0)b,c
Antral follicle count 21.5 (4.0–70.0) 20.5 (4.0–109.0) 33.0 (4.0–132.0)b,c 36.0 (4.0–220.0)b,c
Volume right ovary 4.95 (1.26–23.57) 3.71 (0.10 – 40.67) 8.90 (0.80–50.59)b,c 9.16 (0.53–131.33)b,c
Volume left ovary 4.31 (0.46–26.69) 3.60 (0.39–21.18) 7.64 (0.10–80.15)b,c 7.90 (0.10–182.21)b,c
Total ovarian volume 9.98 (2.03–50.25) 8.46 (0.78–53.45) 16.71 (2.89–130.74)b,c 17.52 (1.26–200.62)b,c
Values represent the median (range). 
AMH, anti-Müllerian hormone; HH, hypothalamic hypogonadism; PCOS, polycystic ovary syndrome.
aThe lower limit of detection for AMH was 0.1 µg/L.
bP < 0.001 compared with controls. 
cP < 0.001 compared with HH P values obtained through Mann-Whitney U test.
Figure 1. (A) Boxplot showing serum anti-Müllerian hormone levels in the control, HH, and age-matched PCOS group. (B) Boxplot showing antral 
follicle count in the control, HH, and age-matched PCOS group. *P < 0.001 compared with the control group. **P < 0.001 compared with the 
control group and the HH group.
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/5/e2008/5805240 by Erasm
us U
niversiteit R
otterdam
 user on 28 M
ay 2020
e2012  Alemyar et al  AMH and Ovarian Morphology in Women J Clin Endocrinol Metab, May 2020, 105(5):e2008–e2014
control group. In the HH group, 5.0% had biochem-
ical hyperandrogenism compared with 3.6% in the con-
trol group. Clinical hyperandrogenism did occur more 
often in the HH group compared to the control group: 
in the HH group, 10.1% had clinical hyperandrogenism 
compared with 2.4% in the control group (P < 0.05) 
(Table 3).
In our control group, we found that 3.6% (3 patients) 
had biochemical hyperandrogenism but the entire group 
had normal testosterone levels: this was caused by low 
SHBG levels in specifically these 3 patients resulting in 
a high FAI.
Rotterdam Criteria for PCOS in women with HH
In the HH group, 58 (36%) women met the 
Rotterdam Criteria for PCOS, if gonadotropin and es-
trogen levels were not taken into account. The pheno-
types for meeting the Rotterdam Criteria for PCOS 
in the HH group were: 39 (24.5%) had PCOM and 
amenorrhea/oligomenorrhea, 11 (6.9%) had amenor-
rhea/oligomenorrhea and hyperandrogenism, and 8 
(5.0%) had PCOM, amenorrhea/oligomenorrhea and 
hyperandrogenism.
As for the control group: only 1 patient met the 
Rotterdam Criteria for PCOS. This patient had both 
PCOM and hyperandrogenism.
Discussion
This large study shows that AMH serum levels are in-
creased in women with HH compared with healthy 
regularly cycling ovulatory controls, but that their levels 
are lower than those of women with PCOS. Antral fol-
licle count and total ovarian volume are, however, not 
increased in women with HH compared with healthy 
controls.
These findings are in discordance with results from a 
small study including 28 women with HH (16), which 
reported higher AMH levels and higher FNPO in women 
with HH compared with controls. However, of these 28 
women, only 11 had validated data available for FNPO. 
This same group (24) also reported that women with 
HH had higher AMH levels and a higher mean ovarian 
volume compared with controls. These findings are also 
in discordance with results from a study published by 
Luisi et  al (25)., in which no significant difference in 
AMH was found between a group of women with hypo-
thalamic amenorrhea and a group of women consisting 
of healthy controls.
We hypothesize that the increase in AMH levels in 
the HH group compared with the control group in the 
current study, whereas there was no increase in follicle 
count, can be explained by the presence of a relatively 
large pool of antral follicles <2 mm in diameter. These 
follicles are not counted during transvaginal ultrason-
ography although they do secrete AMH. Support for 
this explanation is found in the study performed by 
Weenen et al., (26) in which, after staining with AMH 
antibodies, histological specimens showed considerable 
AMH expression in antral follicles <2 mm in diameter. 
Moreover, although we did not find an increase in an-
tral follicles in the HH group, increased numbers of 
antral follicles may not necessarily be required for ele-
vated AMH levels. Pellatt et al. (27) suggest that AMH 
production per antral follicle may be increased in dif-
ferent pathological conditions leading to anovulation 
and could drive increased levels of AMH. This may 
also explain the higher AMH levels with similar fol-
licle counts, as was also found in the study by Jonard 
et al. (28). On the 1 hand, the authors of this study sug-
gest that increased AMH production per antral follicle 
might indeed be the cause for increased AMH levels 
Table 3. Biochemical and clinical hyperandrogenism given as numbers and percentages among the study 
groups
Controls HH Age-Matched PCOSa PCOS
N 83 159 318 3640
Biochemical hyperandrogenism 3 (3.6%) 8 (5.0%) 182 (57.2%)c,d 1972 (54.2%)c,d
Clinical hyperandrogenism score 2 (2.4%) 16 (10.1%)b 98 (30.8%)c,d 986 (27.1%)c,d
Polycystic ovarian morphology 20 (24.1%) 50 (31.4%) 259 (81.4%)d,e 3185 (87.5%)d,e
Values represent the number (percentage) of women.  Biochemical hyperandrogenism was defined as Free-androgen-index > 2.9; clinical 
hyperandrogenism was defined as Ferriman-Gallwey score ≥ 5;pPolycystic ovarian morphology was defined as having 12 or more antral follicles in 
the left or right ovary. 
aAge matched with HH group.
bP < 0.05 compared to controls (Fischer’s Exact Test)
cP < 0.001 compared to controls (Fischer’s Exact Test).
dP < 0.001 compared to HH (Pearson’s χ2 test).
eP < 0.001 compared to controls (Pearson’s χ2 test).
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without a coincident increase in antral follicle count in 
women with hypothalamic amenorrhea. On the other 
hand, they also took into consideration the possibility 
of an increased number of small follicles undetectable 
on ultrasound because of their size.
Another explanation might be that the follicles that 
produce large amounts of AMH are the healthiest ones 
and therefore they will respond better to exogenous 
gonadotropins. Indeed, the predictive value of AMH 
levels in women with HH has been reported by van 
Elburg et  al. They showed that as baseline levels of 
AMH increased, so did the probability of weight in-
crease and recovery of menstrual cycles (29).
In line with the similar number of follicles in women 
from the HH group and control group, PCOM did 
not occur more often in women with HH compared 
with healthy ovulatory controls. Indeed, similar find-
ings were reported in a study performed by Lie Fong 
et al. (3).
Biochemical hyperandrogenism did not occur more 
often in women with HH than in the control group, 
and testosterone levels were in fact, as to be expected 
(30), lower in women with HH. However, clinical 
hyperandrogenism did occur more often in women 
with HH than in healthy controls. Indeed, women with 
HH may experience, for example, acne, alopecia, and/
or hirsutism (18), and physicians should be aware of 
these symptoms and discuss this with their patient. 
Moreover, treatment of these distressing complaints 
can be important steps in optimizing quality of life in 
these women. That clinical hyperandrogenism was ob-
served more often in the HH group without an obvious 
increase in FAI may indicate disturbances at the level of 
the androgen receptor or androgen processing. Future 
research is warranted to explore this finding.
Interestingly, we found that more than one-third of 
the HH group met the Rotterdam Criteria for PCOS. 
Indeed, other studies (31) support this finding, showing 
that 86% women with HH met the Rotterdam Criteria 
for PCOS. This stresses the need for a correct distinction 
between HH and PCOS because false-positive diagnoses 
may lead to employment of treatment options that are 
suboptimal for these women.
In the latest guidelines for diagnosing PCOS (18), 
a cutoff criterion for PCOM is described as 20 antral 
follicles per ovary, instead of the 12 antral follicles 
per ovary we have used as a cutoff. Because our em-
ployed ultrasound had a capacity of 4 to 8 MHz, (and 
the guideline changed the threshold of PCOM because 
of improving technologies with improving bandwidth 
>8 MHz), we chose to maintain the analyses using the 
cutoff of 12 antral follicles per ovary. Regardless, when 
changing the cutoff to 20 antral follicles per ovary, 
we found that 20.3% met the Rotterdam Criteria for 
PCOS. That is still more than one-fifth of women who 
have hypothalamic hypogonadism.
In light of recent debate whether the cumbersome 
ultrasound assessment of PCOM might be replaced in 
time by a single AMH measurement (12), the need for 
initial assessment of FSH, LH, and E2 levels becomes 
even more important. In particular, those women with 
HH and elevated levels of AMH will be erroneously 
misdiagnosed as having PCOS.
In conclusion, we report increased AMH levels in 
women with HH compared with healthy controls, 
and we therefore stress the importance of measuring 
gonadotropins and E2 in the diagnostic workup of an-
ovulatory patients because AMH and sonographic data 
are not specific enough to distinguish between PCOS 
and HH.
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